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BACKGROUND: Antiphospholipid syndrome is an autoimmune, adjusted odds ratio, 0.71; 95% confidence interval, 0.51e0.90). Also, they
hypercoagulable state that is caused by antiphospholipid antibodies. Anti-
cardiolipin antibodies, anti-b2 glycoprotein-I, and lupus anticoagulant are
the main autoantibodies found in antiphospholipid syndrome. Despite the
amassed body of clinical knowledge, the risk of obstetric complications that
are associated with specific antibody profile has not been well-established.
OBJECTIVE: The purpose of this study was to assess the risk of ob-
stetric complications in women with primary antiphospholipid syndrome
that is associated with specific antibody profile.
STUDY DESIGN: The Pregnancy In Women With Antiphospholipid
Syndrome study is a multicenter, retrospective, cohort study. Diagnosis and
classification of antiphospholipid syndrome were based on the 2006 Inter-
national revised criteria. All women included in the study had at least 1
clinical criteria for antiphospholipid syndrome, were positive for at least 1
antiphospholipid antibody (anticardiolipin antibodies, anti-b2 glycoprotein-I,
and/or lupus anticoagulant), and were treated with low-dose aspirin and
prophylactic low molecular weight heparin from the first trimester. Only
singleton pregnancies with primary antiphospholipid syndrome were
included. The primary outcomewas live birth, defined as any delivery of a live
infant after 22weeks gestation. The secondary outcomeswere preeclampsia
with and without severe features, intrauterine growth restriction, and still-
birth. We planned to assess the outcomes that are associated with the
various antibody profile (test result for lupus anticoagulant, anticardiolipin
antibodies, and anti-b2 glycoprotein-I).
RESULTS: There were 750 singleton pregnancies with primary anti-
phospholipid syndrome in the study cohort: 54 (7.2%) were positive for lupus
anticoagulant only; 458 (61.0%) were positive for anticardiolipin antibodies
only; 128 (17.1%) were positive for anti-b2 glycoprotein-I only; 90 (12.0%)
were double positive and lupus anticoagulant negative, and 20 (2.7%) were
triple positive. The incidence of live birth in each of these categories was
79.6%, 56.3%, 47.7%, 43.3%, and 30.0%, respectively. Compared with
womenwith only 1 antibody positive test results, womenwithmultiple antibody
positive results had a significantly lower live birth rate (40.9% vs 56.6%;Cite this article as: Saccone G, Berghella V, Maruotti
GM, et al. Antiphospholipid antibody profile based
obstetric outcomes of primary antiphospholipid
syndrome: the PREGNANTS study. Am J Obstet Gynecol
2017;216:525.e1-12.
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http://dx.doi.org/10.1016/j.ajog.2017.01.026were at increased risk of preeclampsia without (54.5% vs 34.8%; adjusted
odds ratio, 1.56; 95% confidence interval, 1.22e1.95) and with severe
features (22.7% vs 13.8%, adjusted odds ratio, 1.66; 95% confidence
interval, 1.19e2.49), of intrauterine growth restriction (53.6% vs 40.8%;
adjusted odds ratio, 2.31; 95% confidence interval, 1.17e2.61) and of still-
birth (36.4% vs 21.7%; adjusted odds ratio, 2.67; 95% confidence interval,
1.22e2.94). In women with only 1 positive test result, women with anti-b2
glycoprotein-I positivity present alone had a significantly lower live birth rate
(47.7% vs 56.3% vs 79.6%; P<.01) and a significantly higher incidence of
preeclampsia without (47.7% vs 34.1% vs 11.1%; P<.01) and with severe
features (17.2% vs 14.4% vs 0%; P¼.02), intrauterine growth restriction
(48.4% vs 40.1% vs 25.9%; P<.01), and stillbirth (29.7% vs 21.2% vs 7.4%;
P<.01) comparedwithwomenwith anticardiolipin antibodies andwithwomen
with lupus anticoagulant present alone, respectively. In the group of women
with >1 antibody positivity, triple-positive women had a lower live birth rate
(30% vs 43.3%; adjusted odds ratio,0.69; 95% confidence interval,
0.22e0.91) and a higher incidence of intrauterine growth restriction (70.0%
vs 50.0%; adjusted odds ratio,2.40; 95% confidence interval, 1.15e2.99)
compared with double positive and lupus anticoagulant negative women.
CONCLUSION: In singleton pregnancies with primary antiphospholipid
syndrome, anticardiolipin antibody is the most common sole antiphospholipid
antibody present, but anti-b2 glycoprotein-I is the one associated with the
lowest live birth rate and highest incidence of preeclampsia, intrauterine
growth restriction, and stillbirth, compared with the presence of anticardiolipin
antibodies or lupus anticoagulant alone.Womenwith primary antiphospholipid
syndrome have an increased risk of obstetric complications and lower live birth
rate when<1 antiphospholipid antibody is present. Despite therapy with low-
dose aspirin and prophylactic low molecular weight heparin, the chance of a
liveborn neonate is only 30% for triple-positive women.
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eclampsia, preterm birth, thrombophiliantiphospholipid syndrome (APS)A is an autoimmune, hypercoagula-
ble state caused by evidence of anti-
phospholipid antibodies (APA) 1 that is
deﬁned as venous or arterial throm-
bosis and/or pregnancy morbidity in
patients with persistent laboratory
evidence of APA. AnticardiolipinMAY 2017 Ameriantibodies (aCL), anti-b2 glycoprotein-
I (ab2GPI), and lupus anticoagulant
(LA) are the main autoantibodies found
in APS.2
There are 2 types of APS: primary APS
refers to a patient with APS but no
other autoimmune disorders; secondary
APS refers to a patient with othercan Journal of Obstetrics& Gynecology 525.e1
TABLE 1
Clinical (must meet at least 1) and laboratory (must meet at least 1) criteria for the diagnosis of antiphospholipid
syndrome based on the 2006 International consensus statement2
Clinical criteria
Vascular thrombosis: 1
clinical episodes of arterial,
venous, or small vessel
thrombosis
Pregnancy morbidity: 1
unexplained fetal death at 10
weeks gestation
Pregnancy morbidity: 1
preterm births at <34 weeks
gestation because of severe
preeclampsia or intrauterine
growth restriction
Pregnancy morbidity: 3
unexplained pregnancy
losses at <10 weeks gestation
Laboratory criteriaa
Lupus anticoagulantb Anticardiolipin antibody of immunoglobulin
G or M isotype >40 GPL or MPL, or >99th
percentile with the use of commercially
available enzyme-linked immunosorbent assay
Anti-b2 glycoprotein-I of immunoglobulin
G or M isotype in titer >99th percentile for
a normal population as defined by the laboratory
performing the test with the use of commercially
available enzyme-linked immunosorbent assay
GPL, G phospholipids; MPL, M phospholipids.
a Abnormal laboratory tests must occur on>1 occasion,12 weeks apart, and within a 5-year time frame; b Examples are lupus anticoagulant, dilute Russell’s viper venom time, or activated partial
thromboplastin time test.
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temic lupus erythematosus.1,2
Pregnant women with APS are at
increased risk of obstetric complica-
tions that include pregnancy loss, pre-
eclampsia, intrauterine growth
restriction (IUGR), stillbirth, and pre-
term birth (PTB).1 According to the
American College of Obstetricians and
Gynecologists (ACOG), in women with
APS, prophylactic doses of heparin and
low-dose aspirin during pregnancy
should be considered.3 However,
despite the amassed body of clinical
knowledge,1-3 the risk of obstetric
complications according to the APA
proﬁle has not been well-established
and is still subject of debate.1-3
Thus, the aim of our study was to
assess the risk of obstetric complications
in women with primary APS according
to the APA proﬁle (test result for LA,
aCL, and ab2GPI).
Methods
Study design and participants
The PREGNANTS (PREGNancy in
women with ANTiphospholipid Syn-
drome) study is multicenter, retrospec-
tive, cohort study. Clinical records of all
consecutive pregnant women with pri-
mary APS, who were referred to 7 Italian
University Hospitals (University of525.e2 American Journal of Obstetrics& GynecolNaples “Federico II,” University of
Bologna, University of Parma, University
of Modena, University of Udine, Uni-
versity of Padua, and University of Roma
“Tor Vergata”) from January 2007 to
April 2016, were collected in a dedicated
merged database. Data for all consecu-
tive women with singleton pregnancies
who previously had had a diagnosis of
primary APS2 and were referred to our
Divisions for counselling were included
in the database. Only women with
singleton pregnancies and only those
who were visited at least once in the ﬁrst
trimester (<12 weeks) of their preg-
nancy were analyzed. Women with
multiple pregnancies were excluded.
Antiphospholipid antibodies testing
and management
At the ﬁrst trimester visit, all women
were counselled; APA was tested for
conﬁrmatory testing, and therapy was
begun.
Women were tested for aCL, ab2GPI,
and LA and were treated with both low-
dose aspirin (100 mg per day) and pro-
phylactic low molecular weight heparin
(LMWH; dalteparin 5000 U subcutane-
ously every 12 hr) in case of no history of
arterial or venous thrombosis.3 In case of
a history of thrombosis, women were
treated with LMWH at therapeutic levelsogy MAY 2017(either enoxaparin 1 mg/kg every 12 hr
subcutaneously or dalteparin 200 U/kg
every 12 hr subcutaneously). Therapy
was begun as soon as APS was conﬁrmed
and continued until 6 weeks after de-
livery.3 If venous thromboembolism
(VTE) occurred during the current
pregnancy, women were then treated
with LMWH at therapeutic levels.3
Women who did not received low-
dose aspirin and LMWH starting from
the ﬁrst trimester (<12 weeks gestation)
and those who received other therapies
(eg, corticosteroids, intravenous immu-
noglobulin) were excluded from the
analysis.
APA were tested in each participating
center with the use of the same cut-offs2
and the same techniques at a core labo-
ratory in the ﬁrst trimester4,5 to stan-
dardize the testing across all centers.
ACL
ACL was tested with the use of the
standardized enzyme-linked immuno-
sorbent assay for cardiolipin.4
Ab2GPI
A maxisorp microtitre plate was coated
with beta 2 glycoprotein 1 antigen
diluted in borate-buffered saline solu-
tion pH 9.6 and incubated at 4C over-
night. The plate was then washed 2 times
FIGURE 1
Study algorithm
Study flow chart.
APS, antiphospholipid syndrome.
Saccone et al. Obstetric outcomes in primary anti-
phospholipid syndrome. Am J Obstet Gynecol 2017.
TABLE 2
Antibody profile of the 750 women included
Variable
Incidence
(n¼750), n (%)
Classification according to the 2006 International
consensus statement2
LAþ/aCLþ/ab2GPIþ 20 (2.7) Type I (triple-positive)
LAe/aCLþ/ab2GPIþ 90 (12.0) Type I (double-positive and LA negative)
LAþ/aCLe/ab2GPIe 54 (7.2) Type IIa (single-positive)
LAe/aCLþ/ab2GPIe 458 (61.0) Type IIb (single-positive)
LAe/aCLe/ab2GPIþ 128 (17.1) Type IIc (single-positive)
ab2GPI, anti-b2 glycoprotein-I; aCL, anticardiolipin antibody; LA, lupus anticoagulant.
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The plate was incubated 2 hours at room
temperature. At the end of incubation,the plate was washed a further 3 times;
after which, 100 mL of working strength
detection antibody (goat anti-Human
immunoglobulin G or M alkaline phos-
phatase conjugate; Sigma Chemical
Company, St Louis, MO) was added to
each well. Three more washes were per-
formed. Absorbance was read on an
automated microplate reader.
LA
LA was detected with the use of a panel
of 3 tests that included the dilute
Russell’s viper venom time, a lupus
anticoagulant-sensitive partial throm-
boplastin time, and the dilute pro-
thrombin time.
Therefore, all women included in the
study had singleton pregnancies, had a
previous diagnosis of primary ASP
based on the revised classiﬁcation
criteria (Table 1),2 had a positive
conﬁrmatory testing in the ﬁrst
trimester, and received low-dose aspirin
and LMWH.
Outcomes
The primary outcome was live birth,
deﬁned as any delivery of a live infant at
>22 weeks gestation. The main sec-
ondary outcomes were preeclampsia
without severe features,6 preeclampsia
with severe features,6 IUGR,7 and still-
birth (fetal death at >22 weeks gesta-
tion). Other secondary outcomes were
very preterm IUGR,7 placental abrup-
tion (detachment or separation of the
placenta at any time before delivery),
VTE in the index pregnancy, pregnancy
loss at 22 weeks gestation, PTB atMAY 2017 Ameri<37 weeks gestation, and neonatal
death (death of a live-born baby within
the ﬁrst 28 days of life). Given that
women with history of VTE have worse
pregnancy outcomes compared with
those without a history of VTE,1-3 we
planned to assess the primary outcome
(ie, live birth) in subgroup analysis ac-
cording to the history of vascular
thrombosis.
Diagnosis of preeclampsia without
severe features and preeclampsia with
severe features were based on the ACOG
guidelines.6 IUGR was deﬁned as ultra-
sound estimated fetal weight of <10th
percentile for gestational age on the
reference chart.7 Severe very preterm
IUGR was considered present in
women with a fetal abdominal circum-
ference of <10th percentile for gesta-
tional age on the reference chart and
abnormal umbilical artery Doppler with
a pulsatility index of >95th percentile of
the Doppler reference chart at 24e32
weeks.7
The diagnosis of APS required the
presence of at least 1 clinical and 1 lab-
oratory criteria,4,5 as reported in
Table 1.2Womenwith primary APSwere
divided into 2 groups according to the
antibody proﬁle2: type I, >1 laboratory
criterion present in any combination;
type II, positivity to a single test alone.
The type Iwomenwere then divided into
2 subgroups: those with triple positivity
and those with double positivity. The
type II women were divided into 3 sub-
groups: IIa (LA present alone), IIb (aCL
present alone), and IIc (ab2GPI present
alone).2can Journal of Obstetrics& Gynecology 525.e3
FIGURE 2
Antibody profile of the 750 women who were included
Antibody profile of the 750 included women.
ab2GPI, anti-b2 glycoprotein-I; aCL, anticardiolipin antibody; LA, lupus anticoagulant.
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through the text to make them easier to
read.TABLE 3
Characteristics of the 110 type I (ie, >1
pregnant women with primary antipho
Characteristics
Age, ya
Ethnicity, n (%)
White
Non-whiteb
Body mass index, kg/m2a
Smoking n (%)
Diabetes mellitus (including gestational diabetes
Live birth history, n (%)
1 Vascular thrombosis, n (%)
1 Unexplained fetal death at 10 weeks gest
1 Severe preeclampsia or intrauterine growth
<34 weeks gestation, n (%)
3 Unexplained pregnancy losses at <10 week
N (%)
Median (range)
a Data are presented as mean differencestandard deviation; b
Saccone et al. Obstetric outcomes in primary antiphospholip
525.e4 American Journal of Obstetrics& GynecolTo assess the strongest antibody prog-
nosticmarker and to assess the chance of a
liveborn neonate and likelihood ofantibody positivity) and the 640 type II (
spholipid syndrome
>1 Positive antibody
(n¼110; 14.7%)
27.44.5
99 (90.0)
11 (10.0)
25.312.4
9 (8.1)
mellitus), n (%) 5 (4.5)
35 (31.8)
35 (31.8)
ation, n (%) 30 (27.3)
restriction at 50 (45.5)
s gestation
27 (24.5)
4.7 (3e11)
Includes Hispanic, Asiatic, Black African; c Statistically significant.
id syndrome. Am J Obstet Gynecol 2017.
ogy MAY 2017obstetric complications in each antibody
proﬁle, we assessed the primary and
the secondary outcomes in the following
analyses, separately: type I (either LAe/
aCLþ/ab2GPIþ or LAþ/aCLþ/
ab2GPIþ) vs type II women (either LAþ/
aCLe/ab2GPIe or LAe/aCLþ/ab2GPIe
or LAe/aCLe/ab2GPIþ); type IIa (LAþ/
aCLe/ab2GPIe) vs IIb (LAe/aCLþ/
ab2GPIe) vs IIc (LAe/aCLe/ab2GPIþ);
and triple-positive (LAþ/aCLþ/
ab2GPIþ) vs double-positive.
Statistical analysis
Statistical analysis was performed with
the use of Statistical Package for Social
Sciences software (version 19.0; IBM Inc,
Armonk, NY).
Data are shown as meansstandard
deviation or as medians (range) or as
number (percentage). Univariate com-
parisons of dichotomous data were
performed with the use of the Fisher’s
exact test. Comparisons between
groups were performed with the use of
the Mann-Whitney U test to test group
medians with range and with the use of
the T-test or the 1-way analysis ofie, positivity to a single test alone)
Single positive antibody
(n¼640; 85.3%) P value
28.29.3 .11
.14
600 (93.8)
40 (6.2)
25.811.2 .74
59 (9.2) .47
29 (4.5) .93
230 (35.9) .24
84 (13.1) <.01c
160 (25.0) .19
290 (45.3) .47
.08
155 (24.2)
4.9 (3e10)
TABLE 4
Primary and secondary outcomes in the 110 type I (ie, with >1 antibody positivity) and in the 640 type II (ie, positivity to
a single test alone) pregnant women with primary antiphospholipid syndrome
Outcome
<1 Positive
antibody
(n¼110; 18.3%),
n (%)
Single positive
antibody
(n¼640; 81.7%),
n (%)
Crude odds ratio
(95% confidence
interval)
Adjusted odds ratio
(95% confidence
interval)a
Adjusted odds ratio
(95% confidence
interval)b
Live birth 45 (40.9) 362 (56.6) 0.70 (0.54e0.90)c 0.71 (0.51e0.90)c 0.71 (0.45e0.91)c
Preeclampsia without
severe features
60 (54.5) 223 (34.8) 1.56 (1.27e1.93)c 1.56 (1.22e1.95)c 1.55 (1.20e1.95)c
Preeclampsia with severe
features
25 (22.7) 88 (13.8) 1.64 (1.09e2.47)c 1.66 (1.19e2.49)c 1.66 (1.19e2.79)c
Intrauterine growth
restriction
59 (53.6) 261 (40.8) 2.55 (1.07e2.59)c 2.31 (1.17e2.61)c 2.29 (1.07e2.65)c
Severe very preterm
intrauterine growth
restriction
31 (28.2) 86 (13.4) 2.09 (1.44e3.04)c 2.09 (1.34e3.24)c 2.09 (1.14e3.54)c
Placenta abruption 2 (1.8) 1 (0.2) 22.12 (1.07e457.47)c 20.02 (0.77e551.71) 31.02 (0.77e751.71)
Venous thromboembolism
in the current pregnancy
20 (18.2) 37 (5.8) 3.69 (2.24e6.08)c 2.86 (2.14e7.08)c 2.89 (2.14e7.18)c
Pregnancy loss 25 (22.7) 139 (21.7) 1.04 (0.71e1.53) 1.03 (0.71e1.43) 1.03 (0.71e1.53)
Preterm birth 45 (40.9) 195 (30.5) 1.37 (1.13e1.75)c 1.34 (1.03e1.74)c 1.24 (1.03e1.84)c
Stillbirth 40 (36.4) 139 (21.7) 2.67 (1.24e2.88)c 2.67 (1.22e2.94)c 2.13 (1.12e2.95)c
Neonatal death 4 (3.6) 14 (2.2) 1.27 (0.43e3.79) 1.22 (0.44e4.12) 1.12 (0.44e4.22)
a Adjusted for history of vascular thrombosis (Table 3); b Adjusted for all variables reported in Table 3; c Statistically significant.
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Logistic regression, presented as un-
adjusted odds ratio (crude odds ratio) or
adjusted odds ratio (aOR) with the 95%
of conﬁdence interval (CI),8 was per-
formed for primary and secondary out-
comes. Adjusted analysis was performed
to correct data for relevant baseline
characteristics. Two adjusted analyses
were performed, 1 in which covariates
were included if they statistically differed
between the antibody groups and 1 in
which all potentially relevant baseline
characteristics were added to themodel as
covariates. The latter analysis was per-
formed to show robustness of our re-
sults.9 All results presented in the abstract
and text refer to the ﬁrst adjusted analysis.
A probability value of <.05 was consid-
ered to indicate statistical signiﬁcance.
The study was reported following
the Strengthening the Reporting of
Observational Studies in Epidemiology
guidelines.10Results
During the study period, there were
173,842 deliveries in the 7 centers; 1201
primary APS pregnant women (0.7%)
were identiﬁed. Overall, 750 singleton
pregnancies met the inclusion criteria
and were analyzed retrospectively
(Figure 1). Fifty-four pregnancies
(7.2%) were positive for only LA; 458
pregnancies (61.0%) were positive for
only aCL, and 128 pregnancies (17.1%)
were positive for only ab2GPI; 90 preg-
nancies (12.0%) were LAe/aCLþ/
ab2GPIþ, and 20 pregnancies (2.7%)
were LAþ/aCLþ/ab2GPIþ (Table 2,
Figure 2).
Women with only 1 antibody
positive test results vs women with
multiple positive results
Characteristics of the women
Women with positivity to >1 antibody
test were in general comparable in
terms of baseline characteristics but
had a signiﬁcantly higher rate ofMAY 2017 Ameriprevious vascular thrombosis compared
with women with positivity to a single
test alone (31.8% vs 13.1%; P<.01;
Table 3).
Primary and secondary
outcomes
Compared with women with only 1
antibody positive test results, women
with multiple positive results had
lower live birth rates (40.9% vs 56.6%;
aOR, 0.71; 95% CI, 0.51e0.90) and
a higher incidence of preeclampsia
without (54.5% vs 34.8%; aOR, 1.56;
95% CI, 1.22e1.95) and with severe
features (22.7% vs 13.8%; aOR, 1.66;
95% CI, 1.19e2.49), IUGR (53.6% vs
40.8%; aOR, 1.30; 95% CI, 1.17e2.61),
severe very preterm IUGR (28.2% vs
13.4%; aOR, 2.09; 95% CI, 1.34e3.24),
VTE in the current pregnancy (18.2% vs
5.8%; aOR, 2.86; 95% CI, 2.14e7.09),
PTB (40.9% vs 30.5%; aOR, 1.34; 95%
CI, 1.03e1.74), and stillbirth (36.4% vs
21.7%; aOR, 2.67; 95% CI, 1.22e2.94).can Journal of Obstetrics& Gynecology 525.e5
TABLE 5
Characteristics of the 640 type II (ie, positivity to a single test alone) pregnant women with primary antiphospholipid
syndrome
Characteristics
Lupus anticoagulant
alone (n¼54; 8.4%)
Anticardiolipin antibody
alone (n¼458; 71.6%)
Anti-b2 glycoprotein-I
alone (n¼128; 20.0%) P value
Age, ya 27.46.3 28.47.7 28.24.9 .35
Ethnicity, n (%) .09
White n (%) 50 (92.6) 422 (92.1) 115 (89.8)
Non-whiteb 4 (7.4) 36 (7.8) 13 (10.2)
Body mass index, kg/m2a 26.111.1 25.76.4 25.98.4 .53
Smoking, n (%) 5 (9.3) 51 (11.1) 19 (14.8) .19
Diabetes mellitus (including
gestational diabetes mellitus), n (%)
3 (5.6) 19 (4.1) 6 (4.7) .43
Live birth history, n (%) 20 (37.0) 155 (33.8) 50 (39.1) .12
1 Vascular thrombosis, n (%) 7 (13.0) 61 (13.3) 17 (13.3) .71
1 Unexplained fetal deaths at
10 weeks gestation, n (%)
15 (27.8) 113 (24.7) 32 (25.0) .76
1 Severe preeclampsia or
intrauterine growth restriction at
<34 weeks gestation, n (%)
25 (50.0) 229 (50.0) 58 (45.3) .12
3 Unexplained pregnancy losses
at <10 weeks gestation
.17
N (%) 15 (27.8) 133 (29.0) 35 (27.3)
Median (range) 3.7 (3e4) 4.7 (3e10) 5.1 (3e6)
a Data are presented as mean differencestandard deviation; b Includes Hispanic, Asiatic, Black African.
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placenta abruption, pregnancy loss, and
neonatal mortality (Table 4).
Women with only 1 antibody
positive test results
Characteristics of the women
In the group of the 640 women with
positivity to a single test alone, the LAe/
aCLþ/ab2GPIe women were the most
frequent category (n¼458/640; 71.6%);
the most rare antibody proﬁle was the
LAþ/aCLe/ab2GPIe proﬁle (n¼54/
640; 8.4%); 128 of 640 women (20.0%)
were positive to ab2GPI alone (Table 2).
The 3 subgroups were similar in terms of
maternal demographics andmedical and
obstetric history (Table 5).
Primary and secondary
outcomes
Women with ab2GPI present alone had a
signiﬁcantly lower live birth rate (47.7%
vs 56.3% vs 79.6%; P<.01) and a525.e6 American Journal of Obstetrics& Gynecolsigniﬁcantly higher incidence of pre-
eclampsia without (47.7% vs 34.1% vs
11.1%; P<.01) and with severe features
(17.2% vs 14.4% vs 0%; P¼.02), IUGR
(48.4% vs 40.1% vs 25.9%; P<.01), se-
vere very preterm IUGR (19.5% vs 13.1%
vs 1.9%; P<.01), PTB (32.8% vs 30.4% vs
25.9%; P¼.03), and stillbirth (29.7% vs
21.2% vs 7.4%; P<.01) compared with
women with aCL and with women with
LA present alone, respectively. No dif-
ferences were found in the rate of
placenta abruption, VTE, pregnancy loss,
and neonatal death (Table 6).
Women with multiple positive
results
Characteristics of the women
The group of 110 women with >1 anti-
body positivity included 20 women who
were positive to all 3 laboratory tests
(triple positivity) and 90 patients who
were positive to aCL and ab2GPI but
negative to LA (double positivity); noneogy MAY 2017were double positive with the other 2
possible combinations (Table 7).
Primary and secondary
outcomes
We found that triple-positive women
had lower live birth rates (30% vs 43.3%;
aOR, 0.69; 95% CI, 0.22e0.91) and a
higher incidence of IUGR (70.0% vs
50.0%; aOR, 2.40; 95% CI, 1.15e2.99),
severe very preterm IUGR (35.0% vs
26.7%; aOR, 1.31; 95% CI, 1.27e2.61),
and placenta abruption (10.0% vs 0%;
aOR, 19.77; 95% CI, 1.02e529.77)
compared with double-positive and
negative LAwomen. No differences were
found in the rate of preeclampsia
without and with severe features, VTE,
pregnancy loss, PTB, stillbirth, and
neonatal death (Table 8).
Summary of results
Table 9 is a summary table that shows the
chance of a liveborn neonate and the
TABLE 6
Primary and secondary outcomes in the 640 type II (ie, positivity to a single test alone) pregnant women with primary antiphospholipid syndrome
Outcome
Lupus
anticoagulant
alone (n¼54;
8.4%)
Anticardiolipin
antibody
alone
(n¼458;
71.6%)
Anti-b2
glycoprotein-I
alone (n¼128;
20.0%) P value
Lupus anticoagulant alone vs
anticardiolipin antibody alone
Lupus anticoagulant alone vs
anti-b2 glycoprotein-I alone
Anticardiolipin antibody alone vs
anti-b2 glycoprotein-I alone
Crude odds
ratio (95%
confidence
interval)
Adjusted
odds
ratio (95%
confidence
interval)a
Crude odds
ratio (95%
confidence
interval)
Adjusted odds
ratio (95%
confidence
interval)a
Crude odds
ratio (95%
confidence
interval)
Adjusted odds
ratio (95%
confidence
interval)a
Live birth 43 (79.6) 258 (56.3) 61 (47.7) <.01b 2.55 (1.22e2.66)b 2.41 (1.21e2.65)b 2.69 (1.33e3.11)b 2.67 (1.33e3.10)b 2.21 (1.13e2.34)b 2.18 (1.13e2.44)b
Preeclampsia
without severe
features
6 (11.1) 156 (34.1) 61 (47.7) <.01b 0.31 (0.17e0.64)b 0.33 (0.15e0.70)b 0.20 (0.11e0.41)b 0.23 (0.11e0.51)b 0.70 (0.57e0.82)b 0.71 (0.57e0.89)b
Preeclampsia
with severe
features
0 66 (14.4) 22 (17.2) .02b 0.07 (0.04e0.74)b 0.06 (0.03e1.01) 0.05 (0.01e0.74)b 0.05 (0.01e0.84)b 0.82 (0.55e0.93)b 0.84 (0.54e0.94)b
Intrauterine
growth restriction
14 (25.9) 185 (40.4) 62 (48.4) <.01b 0.62 (0.41e0.82) 0.64 (0.40e0.89)b 0.50 (0.33e0.87)b 0.54 (0.33e0.87)b 0.81 (0.65e0.94)b 0.83 (0.68e0.95)b
Severe very
preterm intrauterine
growth restriction
1 (1.9) 60 (13.1) 25 (19.5) <.01b 0.14 (0.02e0.88)b 0.14 (0.02e0.91)b 0.09 (0.03e0.71)b 0.09 (0.03e0.71)b 0.67 (0.55e0.91)b 0.67 (0.55e0.92)b
Placenta abruption 0 0 1 (0.8) .52 Not estimable Not estimable 0.77 (0.03e10.89) 0.78 (0.03e18.89) 0.09 (0.03e2.28) 0.09 (0.03e2.28)
Venous
thromboembolism
in the current
pregnancy
3 (5.6) 28 (6.1) 6 (4.7) .41 0.90 (0.29e1.99) 0.91 (0.29e2.89) 1.19 (0.31e4.03) 1.19 (0.31e4.57) 1.30 (0.55e2.73) 1.30 (0.55e3.03)
Pregnancy loss 7 (13.0) 103 (22.5) 29 (22.7) .23 0.55 (0.28e1.01) 0.58 (0.28e1.17) 0.57 (0.27e1.22) 0.57 (0.27e1.23) 0.94 (0.58e1.30) 0.95 (0.58e1.31)
Preterm birth 14 (25.9) 139 (30.4) 42 (32.8) .03b 0.83 (0.53e1.05) 0.85 (0.53e1.37) 0.74 (0.47e0.80)b 0.79 (0.47e0.84)b 0.77 (0.70e0.92)b 0.81 (0.70e0.92)b
Stillbirth 4 (7.4) 97 (21.2) 38 (29.7) <.01b 0.37 (0.13e0.89)b 0.35 (0.13e0.91)b 0.25 (0.13e0.56)b 0.25 (0.13e0.66)b 0.71 (0.62e0.88)b 0.71 (0.52e0.89)b
Neonatal death 0 12 (2.6) 2 (1.6) .51 0.53 (0.02e4.56) 0.33 (0.02e5.56) 0.47 (0.12e8.61) 0.47 (0.12e9.61) 2.44 (0.38e5.40) 1.68 (0.38e7.40)
a Adjusted for all variables reported in Table 5; b Statistically significant.
Saccone et al. Obstetric outcomes in primary antiphospholipid syndrome. Am J Obstet Gynecol 2017.
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TABLE 7
Characteristics of the 110 type I (ie, with >1 antibody positivity) pregnant women with primary antiphospholipid
syndrome
Characteristic
Triple-positive
(n¼20; 18.2%)
Double-positive and
lupus anticoagulant
negative (n¼90; 81.8%) P value
Age, ya 27.68.1 27.26.5 .33
Ethnicity, n (%) .97
White 18 (90.0) 81 (90.0)
Non-whiteb 2 (10.0) 9 (10.0)
Body mass index, kg/m2a 25.16.7 25.411.3 .64
Smoking, n (%) 3 (15.0) 6 (6.7) <.01
Diabetes mellitus (including gestational
diabetes mellitus), n (%)
2 (10.0) 3 (3.3) <.01
Live birth history, n (%) 7 (35.0) 28 (31.1) .12
1 Vascular thrombosis, n (%) 7 (35.0) 28 (31.1) .12
1 Unexplained fetal death at 10 weeks gestation, n (%) 6 (30.0) 24 (26.7) .23
1 Severe preeclampsia or intrauterine growth restriction at <34
weeks gestation, n (%)
10 (50.0) 40 (44.4) .47
3 Unexplained pregnancy losses
at <10 weeks gestation
.11
N (%) 6 (30.0) 21 (23.3)
Median (range) 4.9 (3e5) 4.5 (3e11)
a Data are presented as mean differencestandard deviation; b Includes Hispanic, Asiatic, Black African.
Saccone et al. Obstetric outcomes in primary antiphospholipid syndrome. Am J Obstet Gynecol 2017.
Original Research OBSTETRICS ajog.orgmain secondary outcomes for each
identiﬁed antibody proﬁle. The overall
rate of live birth in our cohort was 54.3%
(407/750).
Subgroup analysis
Women without a history of VTE had a
signiﬁcantly higher live birth rate
compared with women without VTE
(56.6% [357/631] vs 42.0% [(50/119];
aOR, 1.80; 95% CI, 1.21e2.67;
Table 10).
Comment
Main findings
In singleton pregnancies with primary
APS, aCL is the most common sole
antibody present (61%), but ab2GPI is
the one associated with the lowest live
birth rate and highest incidences of ob-
stetric complications compared with
aCL or LA alone. Poor pregnancy out-
comes occurred more frequently in
women with >1 antibody positivity.525.e8 American Journal of Obstetrics& GynecolTriple-positive women had a signiﬁ-
cantly higher risk of obstetric compli-
cations compared with double-positive
women. Chance of a liveborn neonate is
only 30% for triple-positive women,
although the rate is 80% for womenwith
positivity to LA alone. Women without
history of vascular thrombosis have a
higher live birth rate compared with
those with history of vascular throm-
bosis. The overall incidence of VTE
during pregnancy in our cohort was
7.6%.
Strengths and limitations
Our study has several strengths. The
number of the included women in our
cohort is substantially higher than in
previous studies on this topic.1,2,11-14
This may be the largest and most
comprehensive study published on the
literature on women with primary
APS.11-14All women were tested, in
the ﬁrst trimester of pregnancy, forogy MAY 2017conﬁrmatory testing; the current latest
accepted deﬁnitions and classiﬁcation
for APS and clinical and laboratory
criteria were used.2 The exclusion of
multiple gestations from the analysis
further provides for a more homoge-
nous sample and is therefore another
strength. Finally, the multicenter nature
of this study makes our results
generalizable.
The most important limitation of
our study is the retrospective approach.
We do acknowledge that some out-
comes were underpowered; however,
those are indeed uncommon outcomes
(eg, placenta abruption, neonatal death)
with an overall rate of <5%. All women
who data were analyzed received low-
dose aspirin and prophylactic LMWH
starting from the ﬁrst trimester3; other
therapies were not analyzed. We did not
assess in our cohort the changing levels
of antibody titers during pregnancy,
and we used the ﬁrst-trimester titers.
TABLE 8
Primary and secondary outcomes in the 110 type I (ie, with >1 antibody positivity) pregnant women with primary
antiphospholipid syndrome
Outcome
Triple-positive
(n¼20; 18.2%),
n (%)
Double-positive and
lupus anticoagulant
negative (n¼90;
81.8%), n (%)
Crude odds ratio
(95% confidence
interval)
Adjusted odds ratio
(95% confidence
interval)a
Adjusted odds ratio
(95% confidence
interval)b
Live birth 6 (30.0) 39 (43.3) 0.69 (0.34e0.87)c 0.69 (0.22e0.91)c 0.61 (0.12e0.92)c
Preeclampsia without
severe features
11 (55.0) 49 (54.4) 1.01 (0.65e1.57) 1.01 (0.64e1.58) 1.01 (0.64e1.78)
Preeclampsia with severe features 5 (25.0) 20 (22.2) 1.45 (0.87e1.56) 1.13 (0.48e2.64) 1.06 (0.38e2.64)
Intrauterine growth restriction 14 (70.0) 45 (50.0) 2.57 (1.15e2.97)c 2.40 (1.15e2.99)c 2.39 (1.13e2.99)c
Severe very preterm intrauterine
growth restriction
7 (35.0) 24 (26.7) 1.47 (1.25e2.01)c 1.31 (1.27e2.61)c 1.31 (1.17e2.51)c
Placenta abruption 2 (10.0) 0 21.67 (1.08e434.78)c 19.77 (1.02e529.77)c 22.77 (1.01e629.77)c
Venous thromboembolism in
the current pregnancy
3 (15.0) 17 (18.9) 0.90 (0.35e2.35) 0.91 (0.41e2.13) 0.93 (0.41e2.03)
Pregnancy loss 5 (25.0) 20 (22.2) 1.13 (0.48e2.64) 1.11 (0.51e3.01) 1.10 (0.41e2.01)
Preterm birth 9 (45.0) 36 (40.0) 1.13 (0.65e1.94) 1.12 (0.65e1.94) 1.10 (0.65e1.99)
Stillbirth 9 (45.0) 31 (34.4) 1.31 (1.12e2.49)c 1.30 (0.74e2.28) 1.22 (0.74e2.38)
Neonatal death 2 (10.0) 2 (2.2) 4.50 (0.67e30.06) 4.44 (0.61e31.16) 4.67 (0.61e39.16)
a Adjusted for all variables reported in Table 7; b Adjusted for smoking and gestational diabetes mellitus; c Statistically significant.
Saccone et al. Obstetric outcomes in primary antiphospholipid syndrome. Am J Obstet Gynecol 2017.
ajog.org OBSTETRICS Original ResearchHowever, data from the Predictors of
Pregnancy Outcomes: Biomarkers in
Antiphospholipid Antibody Syndrome
and Systemic Lupus Erythematosus
study11 showed that APA levels
decreased marginally during pregnancyTABLE 9
Primary and main secondary outcomes
antibody profile
Variable
Triple-positive
(n¼20; 2.7%), n (%)
Live birth 6 (30.0)
Preeclampsia without
severe features
11 (55.0)
Preeclampsia with
severe features
5 (25.0)
Intrauterine growth
restriction
14 (70.0)
Stillbirth 9 (45.0)
Saccone et al. Obstetric outcomes in primary antiphospholipand that changes were not associated
with pregnancy outcome, which sug-
gests that measurement of APA in the
ﬁrst trimester as conﬁrmatory testing in
a core laboratory is sufﬁcient to assess
the risk and that repeat testing throughin pregnant women with primary antipho
Double-positive
and lupus
anticoagulant
negative
(n¼90; 12.0%), n (%)
Lupus
anticoagulant
alone (n¼54; 7.2%),
n (%)
39 (43.3) 43 (79.6)
49 (54.4) 6 (11.1)
20 (22.2) 0
45 (50.0) 14 (25.9)
31 (34.4) 4 (7.4)
id syndrome. Am J Obstet Gynecol 2017.
MAY 2017 Ameripregnancy is unnecessary.3,11 The rate
of adverse pregnancy outcome in our
cohort was higher than previous studies
for women with APS.12-14,16-18 This
could be related to the history of pre-
vious thrombosis because the incidencespholipid syndrome according to the
Anticardiolipin
antibody
alone (n¼458;
61.0%), n (%)
Anti-b2 glycoprotein-I
alone (n¼128;
17.1%), n (%)
258 (56.3) 61 (47.7)
156 (34.1) 61 (47.7)
66 (14.4) 22 (17.2)
185 (40.4) 62 (48.4)
97 (21.2) 38 (29.7)
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TABLE 10
Primary outcome in sensitivity analysis according to the history of vascular thrombosis
Live birth rate in
women without
history of vascular
thrombosis
(n¼631)
Lupus
anticoagulant
alone (n¼48;
7.6%), n (%)
Anticardiolipin
antibody
alone (n¼394;
62.4%), n (%)
Anti-b2 glycoprotein-I
alone (n¼114; 18.1%),
n (%)
Double-positive and
lupus anticoagulant
negative (n¼69; 10.9%),
n (%)
Triple-positive
(n¼ 6; 1.0%),
n (%) P value
Live birth 39 (81.3%) 226 (57.4%) 55 (48.2%) 34 (49.3%) 3 (50.0%) <.01a
Live birth rate in
women with history
of vascular thrombosis
(n¼119)
Lupus
anticoagulant
alone (n¼6;
5.0%), n (%)
Anticardiolipin
antibody
alone (n¼64;
53.8%), n (%)
Anti-b2 glycoprotein-I
alone (n¼14; 11.8%),
n (%)
Double-positive and
lupus anticoagulant
negative (n¼21; 17.6%),
n (%)
Triple-positive
(n¼14; 11.8%),
n (%)
Live birth 4 (66.7%) 32 (50.0%) 6 (42.9%) 5 (23.8%) 3 (21.4%) <.01a
a Statistically significant.
Saccone et al. Obstetric outcomes in primary antiphospholipid syndrome. Am J Obstet Gynecol 2017.
Original Research OBSTETRICS ajog.orgof adverse pregnancy outcome was
considerably lower in the subgroup
analysis of women without a history of
vascular thrombosis (Table 10).
Notably, in our cohort, women without
a history of vascular thrombosis had a
live birth rate of >50%, which is
consistent with previous studies.13,17,18
In the previous studies, the consider-
ably lower sample size did not permit
meaningful subgroup analysis in this
subset of women.12-14,16 An additional
weakness of the study is the different
treatments undergone by patients who
had a history of VTE or not in regards
to LMWH dosing for full anti-
coagulation. This is not a universal
practice,3 even if recommended by ex-
perts,2,18 which limits that aspect of its
external validity. Immunoglobulin G
and M type antibodies were not
analyzed separately. Data on inherited
thrombophilia, including Factor V Lei-
den, were not available.
Interpretation
The diagnostic criteria for APS were ﬁrst
established in the 1999 at Sapporo,
Japan,12 and then revised in the 2006
Sydney International Consensus State-
ment on Investigational Classiﬁcation
Criteria for the APS with the inclusion of
the ab2GPI antibodies.2
Although the risk of VTE and
of adverse pregnancy outcomes in
women with APS is well-established,1
the literature lacks data regarding risk525.e10 American Journal of Obstetrics& Gynecstratiﬁcation within this population ac-
cording to the antibody proﬁle.3,13-16 In
a large and comprehensive systematic
review, Robertson et al13 concluded that
women with acquired thrombophilia,
including APS, are at risk of experiencing
VTE and complications in pregnancy.
They found an increased risk of both
maternal (VTE, preeclampsia, and
autoimmune thrombocytopenia) and
fetal (pregnancy loss and fetal death,
IUGR, and preterm delivery) complica-
tions in women with primary and sec-
ondary APS. However, they did not
report subgroup data according to the
antibody proﬁle.13
APA do not provide merely serum
APS biomarkers but rather exert a direct
pathogenic role in vascular and obstetric
events.2 In particular, ab2GPI provides,
together with prothrombin, the main
epitope targeted by APS.14,15 In the 2012,
Liu et al,16 in a retrospective case-control
study, found that, in pregnant women
LA-negative APS, double-positivity may
be a risk factor for pregnancy loss.
However, this study was limited by the
study design, by the limited outcomes
assessed, and by the small sample size.16
Recently, the PROMISSE study found
that circulating angiogenic factors
measured during early gestation had a
high negative predictive value in ruling
out the development of severe adverse
outcomes among patients with systemic
lupus erythematosus and/or APA
syndrome.11,17ology MAY 2017In the European Registry on Ob-
stetric Antiphospholipid Syndrome
study, a survey of 247 consecutive
cases, Alijotas-Reig et al18 found that
women with obstetric APS showed
differential characteristics than classic
APS and that all laboratory test cate-
gories are needed to avoid false-
negative diagnoses.18 In a European
multicenter retrospective study that
included 196 women with primary and
secondary APS, Alijotas-Reig et al18
found that triple-positive women had
a signiﬁcantly higher risk of obstetric
complications compared with single or
double combinations.
The optimal treatment of women
with primary APS has not been well-
studied.3,19-22 A metaanalysis of ran-
domized trials suggested that prophy-
lactic use of LMWH and low-dose
aspirin may reduce pregnancy loss by
54% in women with APS but no history
of VTE.19 This combined therapy ap-
pears superior to low-dose aspirin alone
or to prednisone.3,19 For women with a
history of VTE, prophylactic LMWH
during pregnancy and until 6 weeks after
delivery is recommended by ACOG; af-
ter delivery, this prophylaxis should be
switched to therapy with coumadin, and
these women should remain on lifelong
anticoagulation therapy.3 Warfarin
therapy is safe in breast-feeding
women.3,23 Notably, most authorities
advise therapeutic anticoagulation for
women with APS and a history of
ajog.org OBSTETRICS Original Researchvascular thrombosis.1,2,4,5,11 Corticoste-
roids and intravenous immunoglobulin
have also been suggested.19-22 A meta-
analysis by Empson et al19 that included
3 randomized trials showed no
improvement in pregnancy outcomes in
women who were treated with predni-
sone. Therefore, the efﬁcacy of cortico-
steroids remains uncertain; because of
the risks associated,19 its use is not rec-
ommended.3 Treatment with intrave-
nous immunoglobulin has been
evaluated in few studies, and the obser-
vations suggest that this therapy may
improve pregnancy outcomes beyond
that observed with heparin and
aspirin.20-22,24,25 However, because the
efﬁcacy has not been proved in appro-
priately powered randomized trials24,25
and the drug is extremely expen-
sive,26,27 its use is discouraged.3
Conclusion
In summary, our ﬁndings provide evi-
dence that pregnant women with pri-
mary APS have an increased risk of
obstetric complications and lower live
birth rates in case of >1 APA positivity.
In women with positivity to a single test
alone, ab2GPI is the one associated with
the lowest live birth rate and highest
incidences of preeclampsia, IUGR, very
preterm IUGR, preterm delivery, and
stillbirth compared with aCL or with LA
alone. n
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